Association of FGF19, FGF21 and FGF23 with carbohydrate metabolism parameters and insulin resistance in patients with chronic kidney disease.
Body composition
Chronic kidney disease
FGF19
FGF21
FGF23
Insulin
Journal
Journal of applied biomedicine
ISSN: 1214-0287
Titre abrégé: J Appl Biomed
Pays: Poland
ID NLM: 101221755
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
01
04
2019
accepted:
11
02
2020
entrez:
15
12
2021
pubmed:
1
8
2020
medline:
11
5
2022
Statut:
ppublish
Résumé
Insulin resistance (IR) is characterised by increased gluconeogenesis in the liver and the resistance of peripheral receptors to insulin. Several factors, including IR, type 2 diabetes, new-onset diabetes after transplant (NODAT) and secondary parathyroidism, are related to chronic kidney disease (CKD). These factors are associated with higher mortality due to the increased risk of cardiovascular complications. Many factors have been identified as potential markers of IR in CKD. These factors include fibroblast growth factors (FGFs), a subfamily of endocrine polypeptides. In this study, we examined the association of FGF19, FGF21 and FGF23 with selected parameters related to carbohydrate metabolism and insulin resistance in non diabetic patients with predialysis CKD and in non diabetic patients after renal transplantation. The study included 108 non diabetic subjects: 40 patients with predialysis CKD, 45 patients with CKD who had undergone renal transplantation, and 23 healthy subjects (control group). In patients who had undergone renal transplantation, concentrations of FGF23 were increased compared to the control group and patients with predialysis CKD. The highest and lowest FGF19 concentrations were observed in CKD patients and in patients who had undergone kidney transplantation, respectively. This difference was statistically significant. Leptin concentrations were higher in CKD patients compared to the control group and patients who had undergone kidney transplantation. There were no statistically significant differences in adiponectin concentrations, lean body mass or fat tissue mass between the studied groups. HOMA-IR and insulin levels were significantly increased in CKD patients and in patients who had undergone renal transplantation in comparison to the control group. The results of the study suggest the involvement of FGF in carbohydrate metabolism and insulin resistance in patients with predialysis CKD, as well as a correlation with kidney function.
Identifiants
pubmed: 34907727
doi: 10.32725/jab.2020.005
doi:
Substances chimiques
FGF19 protein, human
0
FGF23 protein, human
0
Insulin
0
fibroblast growth factor 21
0
Fibroblast Growth Factors
62031-54-3
Fibroblast Growth Factor-23
7Q7P4S7RRE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-69Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Anuwatmatee S, Tang S, Wu BJ, Rye KA, Ong KL (2019). Fibroblast growth factor 21 in chronic kidney disease. Clin Chim Acta 489: 196-202. DOI: 10.1016/j.cca.2017.11.002.
pubmed: 29108880
doi: 10.1016/j.cca.2017.11.002
Asrih M, Veyrat-Durebex C, Poher AL, Lyautey J, Rohner-Jeanrenaud F, Jornayvaz FR (2016). Leptin as a Potential Regulator of FGF21. Cell Physiol Biochem 38(3): 1218-1225. DOI: 10.1159/000443070.
pubmed: 26982498
doi: 10.1159/000443070
Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, et al. (2008). Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149(12): 6018-6027. DOI: 10.1210/en.2008-0816.
pubmed: 18687777
doi: 10.1210/en.2008-0816
Degirolamo C, Sabbà C, Moschetta A (2016). Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 15(1): 51-69. DOI: 10.1038/nrd.2015.9.
pubmed: 26567701
doi: 10.1038/nrd.2015.9
Fayed A, El Nokeety MM, Heikal AA, Abdulazim DO, Naguib MM, El Din UAAS (2018). Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients. Ren Fail 40(1): 226-230. DOI: 10.1080/0886022X.2018.1455594.
pubmed: 29619868
doi: 10.1080/0886022X.2018.1455594
Fernandes-Freitas I, Owen BM (2015). Metabolic roles of endocrine fibroblast growth factors. Curr Opin Pharmacol 25: 30-35. DOI: 10.1016/j.coph.2015.09.014.
pubmed: 26531325
doi: 10.1016/j.coph.2015.09.014
Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, et al. (1998). Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53(5): 1343-1347. DOI: 10.1046/j.1523-1755.1998.00898.x.
pubmed: 9573550
doi: 10.1046/j.1523-1755.1998.00898.x
Fukumoto S (2008). Actions and mode of actions of FGF19 subfamily members. Endocr J 55(1): 23-31. DOI: 10.1507/endocrj.kr07e-002.
pubmed: 17878606
doi: 10.1507/endocrj.kr07e-002
Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, et al. (2013). The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18(3): 333-340. DOI: 10.1016/j.cmet.2013.08.005.
pubmed: 24011069
doi: 10.1016/j.cmet.2013.08.005
Garland JS, Holden RM, Ross R, Adams MA, Nolan RL, Hopman WM, et al. (2014). Insulin resistance is associated with Fibroblast Growth Factor-23 in stage 3-5 chronic kidney disease patients. J Diabetes Complications 28(1) 61-65. DOI: 10.1016/j.jdiacomp.2013.09.004.
pubmed: 24125760
doi: 10.1016/j.jdiacomp.2013.09.004
Han SH, Choi SH, Cho BJ, Lee Y, Lim S, Park YJ, et al. (2010). Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism 59(11): 1656-1662. DOI: 10.1016/j.metabol.2010.03.018. DOI: 10.1371/journal.pone.0122885.
pubmed: 20423749
doi: 10.1016/j.metabol.2010.03.018
Hanks LJ, Casazza K, Judd SE, Jenny NS, Gutiérrez OM (2015). Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One 10(3): e0122885. DOI: 10.1371/journal.pone.0122885.
pubmed: 25811862
doi: 10.1371/journal.pone.0122885
Hu X, Xiong Q, Xu Y, Zhang X, Pan X, Ma X, et al. (2018). Association of serum fibroblast growth factor 19 levels with visceral fataccumulation is independent of glucose tolerance status. Nutr Metab Cardiovasc Dis 28(2): 119-125. DOI: 10.1016/j.numecd.2017.10.009.
pubmed: 29174027
doi: 10.1016/j.numecd.2017.10.009
Hui Q, Jin Z, Li X, Liu C, Wang X (2018). FGF Family: From Drug Development to Clinical Application. Int J Mol Sci 19(7) pii: E1875. DOI: 10.3390/ijms19071875.
pubmed: 29949887
doi: 10.3390/ijms19071875
Isakova T, Cai X, Lee J, Xie D, Wang X, Mehta R, et al. (2018). Longitudinal FGF23 Trajectories and Mortality in Patients with CKD. J Am Soc Nephrol 29(2): 579-590. DOI: 10.1681/ASN.2017070772.
pubmed: 29167351
doi: 10.1681/ASN.2017070772
Kharitonenkov A, Shanafelt AB (2009). FGF21: a novel prospect for the treatment of metabolic diseases. Curr Opin Investig Drugs 10(4): 359-364. PMID: 19337957.
pubmed: 19337957
Kliewer SA, Mangelsdorf DJ (2015). Bile Acids as Hormones: The FXR-FGF15/19 Pathway. Dig Dis 33(3): 327-331. DOI: 10.1159/000371670.
pubmed: 26045265
doi: 10.1159/000371670
Kurşat S, Colak HB, Toraman A, Tekçe H, Ulman C, Bayturan O (2010). Relationship of insulin resistance in chronic haemodialysis patients with inflammatory indicators, malnutrition, echocardiographic parameters and 24 hour ambulatory blood pressure monitoring. Scand J Urol Nephrol 44(4): 257-264. DOI: 10.3109/00365591003733682.
pubmed: 20377496
doi: 10.3109/00365591003733682
Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, et al. (2013). Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 17(5): 779-789. DOI: 10.1016/j.cmet.2013.04.005.
pubmed: 23663741
doi: 10.1016/j.cmet.2013.04.005
Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, et al. (2010). Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 5(12): e15534. DOI: 10.1371/journal.pone.0015534.
pubmed: 21206918
doi: 10.1371/journal.pone.0015534
Liu S, Quarles LD (2007). How fibroblast growth factor 23 works. J Am Soc Nephrol 18(6): 1637-1647. DOI: 10.1681/ASN.2007010068.
pubmed: 17494882
doi: 10.1681/ASN.2007010068
Marchelek-Myśliwiec M, Dziedziejko V, Nowosiad-Magda M, Dołęgowska K, Dołęgowska B, Pawlik A, et al. (2019a). Chronic kidney disease is associated with increased plasma levels of fibroblast growth factors 19 and 21. Kidney Blood Press Res 44: 1207-1218. DOI: 10.1159/000502647.
pubmed: 31614355
doi: 10.1159/000502647
Marchelek-Myśliwiec M, Dziedziejko V, Nowosiad-Magda M, Wiśniewska M, Safranow K, Pawlik A, et al. (2019b). Bone metabolism parameters in haemodialysis patients with chronic kidney disease and in patients after kidney transplantation. Physiol Res 68(6): 947-954. DOI: 10.33549/physiolres.934118.
pubmed: 31647290
doi: 10.33549/physiolres.934118
Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, et al. (2009). Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 71(3): 369-375. DOI: 10.1111/j.1365-2265.2008.03502.x.
pubmed: 19702724
doi: 10.1111/j.1365-2265.2008.03502.x
Nishimura T, Nakatake Y, Konishi M, Itoh N (2000). Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492(1): 203-206. DOI: 10.1016/s0167-4781(00)00067-1.
pubmed: 10858549
doi: 10.1016/s0167-4781(00)00067-1
Reiche M, Bachmann A, Lössner U, Blüher M, Stumvoll M, Fasshauer M (2010). Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters. Horm Metab Res 42(3): 178-181. DOI: 10.1055/s-0029-1243249.
pubmed: 20013647
doi: 10.1055/s-0029-1243249
Sit D, Tanriverdi E, Kayabasi H, Erdem M, Sari H (2018). Is FGF23 effective on insulin resistance in individuals with metabolic syndrome? Horm Mol Biol Clin Investig 35(2) pii: /j/hmbci.2018.35.issue-2/hmbci-2018-0018/hmbci-2018-0018.xml. DOI: 10.1515/hmbci-2018-0018.
pubmed: 30001211
doi: 10.1515/hmbci-2018-0018
Spoto B, Pisano A, Zocalli C (2016). Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol 311(6): F1087-F1108. DOI: 10.1152/ajprenal.00340.2016.
pubmed: 27707707
doi: 10.1152/ajprenal.00340.2016
Stein S, Bachmann A, Lössner U, Kratzsch J, Blüher M, Stumvoll M, et al. (2009). Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 32(1): 126-128. DOI: 10.2337/dc08-1054.
pubmed: 18840768
doi: 10.2337/dc08-1054
Strowski MZ (2017). Impact of FGF21 on glycemic control. Horm Mol Biol Clin Investig 30(2) pii: /j/hmbci.2017.30.issue-2/hmbci-2017-0001/hmbci-2017-0001.xml. DOI: 10.1515/hmbci-2017-0001.
pubmed: 28593912
doi: 10.1515/hmbci-2017-0001
Suassuna PGA, de Paula RB, Sanders-Pinheiro H, Moe OW, Hu MC (2019). Fibroblast growth factor 21 in chronic kidney disease. J Nephrol 32(3): 365-377. DOI: 10.1007/s40620-018-0550-y.
pubmed: 30430412
doi: 10.1007/s40620-018-0550-y
Tanajak P, Pongkan W, Chattipakorn SC, Chattipakorn N (2018). Increased plasma FGF21 level as an early biomarker for insulin resistance and metabolic disturbance in obese insulin-resistant rats. Diab Vasc Dis Res 15(3): 263-269. DOI: 10.1177/1479164118757152.
pubmed: 29424246
doi: 10.1177/1479164118757152
Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, et al. (2002). Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143(5): 1741-1747. DOI: 10.1210/endo.143.5.8850.
pubmed: 11956156
doi: 10.1210/endo.143.5.8850
Voytovich MH, Asberg A, Hjelmesaeth J, Jenssen T, Hartmann A (2006). Association between insulin resistance and endothelialdysfunction in renal transplant recipients. Clin Transplant 20(2): 195-199. DOI: 10.1111/j.1399-0012.2005.00465.x.
pubmed: 16640526
doi: 10.1111/j.1399-0012.2005.00465.x
Wojcik M, Dolezal-Oltarzewska K, Janus D, Drozdz D, Sztefko K, Starzyk JB (2012). FGF23 contributes to insulin sensitivity in obese adolescents - preliminary results. Clin Endocrinol (Oxf) 77(4): 537-540. DOI: 10.1111/j.1365-2265.2011.04299.x.
pubmed: 22103239
doi: 10.1111/j.1365-2265.2011.04299.x
Zaheer S, de Boer IH, Allison M, Brown JM, Psaty BM, Robinson-Cohen C, et al. (2017). Fibroblast Growth Factor 23, Mineral Metabolism, and Adiposity in Normal Kidney Function. J Clin Endocrinol Metab 102(4): 1387-1395. DOI: 10.1210/jc.2016-3563.
pubmed: 28323987
doi: 10.1210/jc.2016-3563
Zhang F, Yu L, Lin X, Cheng P, He L, Li X, et al. (2015). Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases. Mol Endocrinol 29(10): 1400-1413. DOI: 10.1210/me.2015-1155.
pubmed: 26308386
doi: 10.1210/me.2015-1155